Spero Therapeutics Inc (SPRO) Implied Volatility Current

Tracking SPRO implied volatility helps you identify when options premiums on Spero Therapeutics Inc are historically cheap or expensive, and where the best trades are hiding. Spero Therapeutics Inc implied volatility reflects the market's expectation of future price movement: when SPRO IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Spero Therapeutics Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For SPRO, tracking metrics like SPRO IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on SPRO signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease.

It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where SPRO implied volatility sits today versus where it has been. Our scanner ranks Spero Therapeutics Inc implied volatility against its historical range, surfaces extremes in SPRO IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Spero Therapeutics Inc IV is rich or cheap — measure it, then act on it.